Stocks and Investing Stocks and Investing
Mon, February 4, 2013
[ 05:45 AM ] - WOPRAI
Keryx Biopharmaceuticals Inc (NASDAQ:KERX), Down .. After BUYINS.NET Report Predicted Stock Would Go
[ 02:47 AM ] - WOPRAI
NCTY, TUES, NNI, HYK Are Seasonally Ripe To Go Down In the Next Five Weeks
[ 02:47 AM ] - WOPRAI
ZBB, TA, TESO, LUNA, CBNJ, PJP Are Seasonally Ripe To Go Down In the Next Five Weeks
[ 02:46 AM ] - WOPRAI
DUA, AIMC, CNK, SHOR, SMED Are Seasonally Ripe To Go Up In the Next Five Weeks
[ 02:46 AM ] - WOPRAI
IDXX, CTRN, BIDU, NCIT, CTCT, ARII Are Seasonally Ripe To Go Up In the Next Five Weeks
[ 02:45 AM ] - WOPRAI
WG, RDEN, MWV, TVL, DPZ, DWA Are Seasonally Ripe To Go Up In the Next Five Weeks
[ 02:45 AM ] - WOPRAI
STO, ASMI, VLCCF, COKE, HTM, ECA Are Seasonally Ripe To Go Up In the Next Five Weeks
[ 01:47 AM ] - WOPRAI
SFLY Expected To Be Up After Next Earnings Releases
[ 01:46 AM ] - WOPRAI
AFL, SIMG, REXI, HAIN, NSR, HBI Expected To Be Up After Next Earnings Releases
[ 01:46 AM ] - WOPRAI
JKHY, HMN, MYGN, TRMB, AKR, PNRA Expected To Be Up After Next Earnings Releases
[ 01:46 AM ] - WOPRAI
FAF, DAN, RRC, WBC, AMSC, HPY Expected To Be Up Before Next Earnings Releases
[ 01:46 AM ] - WOPRAI
CMG, NOA, GLUU, ALTE Expected To Be Down After Next Earnings Releases
[ 01:46 AM ] - WOPRAI
ULTI, ARE, MEAS, ENTR, PACB, PIKE Expected To Be Down After Next Earnings Releases
[ 01:46 AM ] - WOPRAI
HNI, KIM, DRL, CBL, CYTK, CHRW Expected To Be Down After Next Earnings Releases
[ 01:45 AM ] - WOPRAI
EXM, ULGX, BMR, WCN, UNM, EQR Expected To Be Down After Next Earnings Releases
[ 01:45 AM ] - WOPRAI
LUFK, PBH Expected To Be Down Before Next Earnings Releases
[ 01:45 AM ] - WOPRAI
TEF, ORN, BKS, BLKB, VNDA, SIAL Expected To Be Down Before Next Earnings Releases
[ 12:00 AM ] - WOPRAI
Jimmy Bhullar Downgraded (AON) to Hold and Held Target at $59 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Bryan Keane Upgraded (WU) to Strong Buy and Increased Target to $19 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Christopher Turnure Upgraded (SRE) to Buy and Increased Target to $42 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Jay Tobin Upgraded (VLO) to Hold and Held Target at $48 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Jonathan Block Maintained (ALGN) at Strong Buy with Increased Target to $38 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Domingos Falavina Downgraded (BAP) to Hold on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Matthew Murphy Maintained (AEM) at Hold with Decreased Target to $58 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Kenneth Zaslow Maintained (TSN) at Buy with Increased Target to $28 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Michael Rehaut Maintained (BZH) at Hold with Increased Target to $21 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Adam Samuelson Maintained (BERY) at Strong Buy with Increased Target to $20 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
James Fotheringham Maintained (BEN) at Hold with Increased Target to $50 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Jeremy Campbell Maintained (BEN) at Buy with Increased Target to $53 on, Feb 4th, 2013
[ 12:00 AM ] - WOPRAI
Tazeen Ahmad Initiated (BCRX) at Hold and Held Target at $2 on, Feb 4th, 2013

Tazeen Ahmad Initiated (BCRX) at Hold and Held Target at $2 on, Feb 4th, 2013


Published on 2024-10-25 01:48:40 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Initiated "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold and Held Target at $2 on, Feb 4th, 2013.

Tazeen, nor any peers, have made any analyst calls on BCRX in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources